Celgene Sues To Block Dr. Reddy's Revlimid Generic

Law360 (April 13, 2018, 3:22 PM EDT) -- Celgene Corp. on Thursday tried to block Dr. Reddy's Laboratories Ltd. from making and selling a generic version of its blockbuster chemotherapy drug Revlimid, accusing the Indian drugmaker in New Jersey federal court of infringing five patents.

Dr. Reddy's move for U.S. Food and Drug Administration approval before the five patents expire was an act of infringement, Celgene argued. In its February abbreviated new drug application, Dr. Reddy's claimed that its drug wouldn't infringe the patents or that the patents were otherwise invalid or unenforceable....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.